Everolimus (Votubia®) is recommended for use within NHS Wales for the treatment of:
This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent to or lower than the PAS price.
|Medicine name||everolimus (Votubia®)|
|Formulation||1 mg, 2 mg, 3 mg and 5 mg dispersible tablets; 2.5 mg, 5 mg and 10 mg tablets|
|Company||Novartis Pharmaceuticals UK Ltd|
|BNF chapter||Central nervous system|
|AWMSG meeting date||06/12/2022|
|Date of issue||08/12/2022|
See also the AWMSG recommendation for the use of everolimus (Votubia®) for the adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).